Table 1 Baseline characteristics before and after PSM in HCC patients with and without cirrhosis
Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Cirrhosis | No cirrhosis | P | Cirrhosis | No cirrhosis | P | |
N = 797 (%) | N = 584 (%) | N = 474 (%) | N = 474 (%) | |||
Gender (%) | ||||||
Male | 653 (81.9) | 489 (83.7) | 0.423 | 386 (81.4) | 390 (82.3) | 0.8 |
Female | 144 (18.1) | 95 (16.3) | 88 (18.6) | 84 (17.7) | ||
Age [mean (SD)] | 51.75 (10.13) | 53.04 (10.63) | 0.022* | 51.95 (10.04) | 52.85 (10.13) | 0.168 |
Smoking (%) | 290 (36.4) | 233 (39.9) | 0.203 | 169 (35.7) | 181 (38.2) | 0.459 |
Drinking (%) | 172 (21.6) | 156 (26.7) | 0.032* | 109 (23.0) | 108 (22.8) | 1 |
Diabetes (%) | 44 (5.5) | 49 (8.4) | 0.046* | 33 (7.0) | 31 (6.5) | 0.897 |
HBsAg +, n (%) | 718 (90.1) | 463 (79.3) | < 0.001** | 409 (86.3) | 413 (87.1) | 0.774 |
AFP (%) | ||||||
≤ 400 μg/L | 495 (62.1) | 378 (64.7) | 0.347 | 287 (60.5) | 310 (65.4) | 0.139 |
> 400 μg/L | 302 (37.9) | 206 (35.3) | 187 (39.5) | 164 (34.6) | ||
MVI (%) | ||||||
No | 584 (73.3) | 428 (73.3) | 1 | 346 (73.0) | 347 (73.2) | 1 |
Yes | 213 (26.7) | 156 (26.7) | 128 (27.0) | 127 (26.8) | ||
Prophylactic TACE (%) | 319 (40.0) | 238 (40.8) | 0.828 | 195 (41.1) | 190 (40.1) | 0.791 |
ALBI (%) | ||||||
< − 2.6 | 540 (67.8) | 455 (77.9) | < 0.001** | 327 (69.0) | 371 (78.3) | 0.002** |
≥ − 2.6 | 257 (32.2) | 129 (22.1) | 147 (31.0) | 103 (21.7) | ||
NLR (%) | ||||||
≤ 1.5 | 215 (27.0) | 109 (18.7) | < 0.001** | 102 (21.5) | 97 (20.5) | 0.75 |
> 1.5 | 582 (73.0) | 475 (81.3) | 372 (78.5) | 377 (79.5) | ||
Hepatectomy (%) | ||||||
Nonanatomic | 390 (48.9) | 346 (59.2) | < 0.001** | 270 (57.0) | 268 (56.5) | 0.948 |
Anatomic | 407 (51.1) | 238 (40.8) | 204 (43.0) | 206 (43.5) | ||
Portal triad clamping (%) | ||||||
≤ 20 min | 610 (76.5) | 435 (74.5) | 0.416 | 355 (74.9) | 356 (75.1) | 1 |
> 20 min | 187 (23.5) | 149 (25.5) | 119 (25.1) | 118 (24.9) | ||
Intraoperative blood loss (%) | ||||||
≤ 400 ml | 650 (81.6) | 479 (82.0) | 0.88 | 378 (79.7) | 393 (82.9) | 0.243 |
> 400 ml | 147 (18.4) | 105 (18.0) | 96 (20.3) | 81 (17.1) | ||
Intraoperative blood transfusion (%) | 92 (11.5) | 75 (12.8) | 0.517 | 52 (11.0) | 61 (12.9) | 0.423 |
Tumor diameter (%) | ||||||
< 5 cm | 471 (59.1) | 235 (40.2) | < 0.001** | 228 (48.1) | 221 (46.6) | 0.696 |
≥ 5 cm | 326 (40.9) | 349 (59.8) | 246 (51.9) | 253 (53.4) | ||
Number of tumor (%) | ||||||
Single | 508 (63.7) | 367 (62.8) | 0.776 | 292 (61.6) | 294 (62.0) | 0.947 |
Multiple | 289 (36.3) | 217 (37.2) | 182 (38.4) | 180 (38.0) | ||
Pathological grading (%) | ||||||
I/II | 174 (21.8) | 115 (19.7) | 0.369 | 89 (18.8) | 92 (19.4) | 0.869 |
III/IV | 623 (78.2) | 469 (80.3) | 385 (81.2) | 382 (80.6) | ||
Satellite lesions (%) | ||||||
No | 635 (79.7) | 489 (83.7) | 0.065 | 377 (79.5) | 399 (84.2) | 0.077 |
Yes | 162 (20.3) | 95 (16.3) | 97 (20.5) | 75 (15.8) | ||
Macrovascular invasion (%) | ||||||
No | 690 (86.6) | 532 (91.1) | 0.012* | 431 (90.9) | 428 (90.3) | 0.824 |
Yes | 107 (13.4) | 52 (8.9) | 43 (9.1) | 46 (9.7) | ||
Lymphatic metastasis (%) | ||||||
No | 782 (98.1) | 564 (96.6) | 0.083 | 464 (97.9) | 456 (96.2) | 0.178 |
Yes | 15 (1.9) | 20 (3.4) | 10 (2.1) | 18 (3.8) | ||
BCLC stage (%) | ||||||
0/A | 433 (54.3) | 233 (39.9) | < 0.001** | 222 (46.8) | 216 (45.6) | 0.745 |
B/C | 364 (45.7) | 351 (60.1) | 252 (53.2) | 258 (54.4) | ||